CLAIMS

1. B-cell activating factor for use in a method of increasing mucosal immunity in the gastrointestinal tract of infants or sucklings characterized in that it is administered perorally in a preparation comprising 200 to 3500 pg of B-cell activating factor /ml of the preparation.

2. A preparation comprising 200 to 3500 pg of B-cell activating factor /ml of the preparation for use in a method of increasing mucosal immunity immunity in the gastrointestinal tract of infants or sucklings, wherein the preparation is administered perorally.

3. The preparation for use according to claim 2, wherein the preparation contains 400 to 2500 pg of B-cell activating factor /ml of the preparation.

4. The preparation for use according to claim 2, wherein the preparation contains 500 to 2000 pg of B-cell activating factor /ml of the preparation.

5. The preparation for use according to claim 2, wherein the preparation is infant milk formula or suckling milk formula containing B-cell activating factor.

6. The preparation for use according to claim 2, wherein the preparation is a suspension of B-cell activating factor in water.

CLAIMS

1. Use of B-cell activating factor for manufacturing a preparation for increasing mucosal immunity of infants or sucklings.

2. A preparation for peroral administration, destined for stimulation of mucosal immunity of infants or sucklings, characterized in that it contains B-cell activating factor.

3. The preparation according to claim 2, wherein the preparation is infant milk formula or suckling milk formula containing B-cell activating factor.

4. The preparation according to claim 2, wherein the preparation is a suspension of B-cell activating factor in water destined for peroral administration.

5. The preparation according to claim 2, wherein the preparation contains 200 to 3500 pg of B-cell activating factor /ml of the preparation.

6. The preparation according to claim 5, wherein the preparation contains 400 to 2500 pg of B-cell activating factor /ml of the preparation.

7. The preparation according to claim 2, wherein the preparation contains 500 or 2000 pg of B-cell activating factor /ml of the preparation.